Expanding directly observed therapy: Tuberculosis to human immunodeficiency virus

American Journal of Medicine

Volumn 110, Issue 8, 2001, Pages 664-666

  Bangsberg, David R ^a,c   Mundy, Linda M ^b   Tulsky, Jacqueline P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

FINANCIAL MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTIVATION; MULTIDRUG RESISTANCE; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT SELECTION; PRIORITY JOURNAL; SHORT COURSE THERAPY; SHORT SURVEY; TUBERCULOSIS;

EID: 0035368977     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00729-X     Document Type: Editorial

References (24)

1. Directly observed therapy
2. Implications of directly observed therapy in tuberculosis control measures among IDUs
3. Adherence to isoniazid prophylaxis in the homeless: A randomized controlled trial
4. A randomized controlled trial of interventions to improve adherence with isoniazid therapy to prevent tuberculosis in injection drug users
5. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications
6. Effectiveness of interventions to improve patient compliance: A meta-analysis
7. Impact of directly observed therapy on outcomes in HIV clinical trials
8. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
9. Effects of group HIV patient education on adherence to antiretrovirals. A randomized controlled trial
10. Stages of change and decisional balance for 12 problem behaviors
11. Medication adherence strategies for drug abusers with HIV/AIDS
12. Should we pay the patient? Review of financial incentives to enhance patient compliance
13. Considerations on the road to involuntary confinement
14. Compliance with tuberculosis drug regimens: Incentives and enablers offered by public health departments
15. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis
16. Adherence to antiretroviral therapy predicts progression to AIDS
17. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group
18. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
19. Viral resistance, adherence and pharmokinetic indices in patients on successful and failing PI based HAART
20. Efficacy of indinavir (IDV)/ritonavir (RTV)-based regimens (IRBR) among patients with prior protease inhibitor failure
21. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
22. Measuring processes of change: Applications to the cessation of smoking
23. Stages of change for adherence with medication regimens for chronic disease: Development and validation of a measure
24. When should we delay highly active antiretroviral therapy?